The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses

Key Points

• Cognition improves in patients with Alzheimer's disease and type 2 diabetes due to GLP-1 receptor agonists, indicating a possible therapeutic avenue.
• Significant improvement was noted across various cognitive domains, although requires larger trials to confirm.
• Systematic review and meta-analyses methods confirm positive cognitive impacts supported by multiple studies.
• Further research highlights the need for expanded clinical trials to better understand the full impact of GLP-1 on cognition.